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Ischemia related death, myocardial infarction (Q wave and
non-Q wave), target lesion revascularization (PTCA or CABG).
They enrolled 81% of AMI patients with 77% of STEMI.
Thrombus was visible in 87% of the cases and 65% of the
patients showed initial TIMI flow of 0/1. Device success was
98% and 96% of the patients gained TIMI 3 flow post-
procedure. STEMI subgroup clinical analysis revealed a 30
days accumulative MACE of 2.5% with 0% TLR.8
As shown in Fig. 4 which compares outcomes of MGuard
stent versus bare metal stent and thrombus aspiration trials
which clearly shows benefit of use of MGuard stent in terms of
blush grade and ST-segment resolution. Though this com-
parison is not head to head comparison but trials using bare
metal stent and thrombus aspiration were compared with
similar parameters of myocardial blush grade and ST-seg-
ment resolution. This comparison showed 84.6% MBG grade 3
with MGuard as compared to only 44% with use of thrombus
aspiration catheter and >70% ST resolution was seen in 79.6%
compared to 56.6% in patients of trials of thrombus aspiration.
But these data need careful assessment with statistical anal-
ysis and there is further need of RCTs comparing them.10
Based on these earlier trials Gregg Stone et al conducted
MASTER trial to prove use of novel stenteMGuard and rec-
ommended in any PCI when a stent implantation is needed
and there is a risk of complication due to distal embolization
of plaque or thrombus.3
Results of the study showed >70% resolution of ST-
segment in MGuard 29% relative to control arm of routine PCI
using either BMS or DES in patients undergoing primary PCI
with thrombus containing lesions but partial or absent reso-
lution of ST-segment was comparable to control arm.
But this study was limited by the fact that the operators
and research coordinators were not blinded to stent assign-
ment, which possibly introduced some bias. The MGuard
stent e which has a higher profile and is less flexible than
standard stents e was unable to reach or cross the lesion in
4.1% of patients while there were no device failures in the
control group.
There were no significant differences at 30 days in rates of
mortality (0% versus 1.9%, p ¼ 0.06), major adverse cardiac
events (1.8% versus 2.3%, p ¼ 0.75), or any other clinical out-
come. The authors noted, however, that the study was
underpowered to evaluate differences in clinical events or
infarct size and/or improved clinical outcomes and concluded
that there is need for further experience with this device with
larger trial.r e f e r e n c e s
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1. Background
The effect of intensified platelet inhibition for patients with
unstable angina or myocardial infarction without ST-segment
elevation who do not undergo revascularization has not been
delineated.
2. Methods
In this double-blind, randomized trial, in a primary analysis
involving 7243 patients under the age of 75 years receiving
aspirin, we evaluated upto 30 months of treatment with pra-
sugrel (10 mg daily) versus clopidogrel (75 mg daily). In a sec-
ondaryanalysis involving2083patients 75yearsof ageor older,
we evaluated 5 mg of prasugrel versus 75 mg of clopidogrel.
3. Results
At a median follow-up of 17 months, the primary end point of
death from cardiovascular causes, myocardial infarction, or
stroke among patients under the age of 75 years occurred in
13.9% of the prasugrel group and 16.0% of the clopidogrel
group (hazard ratio in the prasugrel group, 0.91; 95% con-
fidence interval [CI], 0.79 to 1.05; p¼ 0.21). Similar results were
observed in the overall population. The prespecified analysis
UA or NSTEMI with angiographically
proven CAD & advised PCI/CABGS, but
who have opted for medical management 
Aspirin (75 mg) OD plus Clopidogrel (75 mg)
OD plus standard medical therapy  
Aspirin (75mg) OD plus Prasugrel (5 mg)
OD plus standard medical therapy  
All patients are followed up for end points like death, non fatal myocardial infarction, heart 
failure, stroke and major or minor bleeding or any revascularisation.
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primary end point) suggested a lower risk for prasugrel among
patients under the age of 75 years (hazard ratio, 0.85; 95% CI,
0.72e1.00; p ¼ 0.04). Rates of severe and intracranial bleeding
were similar in the two groups in all age groups. There was no
significant between-group difference in the frequency of non-
hemorrhagic serious adverse events, except for a higher fre-
quency of heart failure in the clopidogrel group.
4. Conclusions
Among patients with unstable nonangina or myocardial
infarction without ST-segment elevation, prasugrel did not
significantly reduce the frequency of the primary end point, as
compared with clopidogrel, and similar risks of bleeding were
observed.
4.1. Clinical perspective
Prasugrel is the more potent alternative antiplatelet drug as
compared to clopidogrel in the treatment of invasively man-
agedNSTEMI or STEMI as shown in TRITONTIMI 38 in patients
who were treated with invasive strategy. The TRIOLOGY ACS
has tried to answer the use of prasugrel in unstable angina or
NSTEMI patients who are managed medically. The study
population was at high risk, including NSTEMI or UA with
>1 mm of ST depression plus 1 of 4 additional risk criteria:
age  60 years, diabetes, prior MI, prior revascularisation
(percutaneous coronary interventions or coronary artery
bypass grafting). The trial is negative in terms primary end
point of cardiovascular death, MI, or stroke as compared to
clopidogrel. The important limitation of trial was inclusion
criteria as it was not mandatory to do troponin T or I level for
diagnosis and risk stratification of ACS, the troponin T or I
assay was not done in central laboratory, patients were
randomized upto 7 days of acute event and coronary angiog-
raphy was not mandatory. The really high risk ACS patient
with proved CAD might have been treated with invasive
strategy and may not have been included in the trial.
There are two important observations from this trial which
has different implications particularly in Indian scenario.
The use of Prasugrel in patients who underwent coronary
angiography and had more than 30% coronary stenosis i.e. a
group of patients with definitive CAD but are being managed
conservatively. In this subgroup of patient, there was 23%
reduction in primary end point of cardiovascular death, MI, or
stroke. Thus the patients who have established coronary
artery disease and who are at risk of future cardiac event are
benefited with more potent antiplatelet drug.1
Second important observation of the trial was potent
antiplatelet activity of prasugrel as compared to clopidogrel.
The platelet function sub study2 of TRIOLOGY ACS have
shown that the platelet function inhibition was more with
prasugrel than clopidogrel at 30 days among participants
younger than 75 years and weighing 60 kg or more, a sig-
nificant difference that persisted through all time points. Thus
it points out that there is no significant difference in ischemic
outcomes through the first 12 months despite clinical obser-
vations of greater P2Y12 inhibition with prasugrel than withclopidogrel but there is increased risk of bleeding. Thus the
risk of bleeding outweighs the benefit of more potent anti-
platelet activity of prasugrel in treatment of patient subset
included in TRIOLOGY ACS.
In the trial the dose of prasugrel was reduced to 5 mg in
patients more than 75 years of age and body weight less than
60 kg. The question of efficacy of low dose prasugrel have been
tested in recently published FEATHER trial3 that has shown
that prasugrel 5 mg in low body weight (<60 kg) reduces pla-
telet reactivity to a similar extent as prasugrel 10 mg in high
body weight (>60 kg), supporting the use of prasugrel 5 mg in
low body weight patients by doing platelet function assay.
In India we have large number of patients who had ACS
who are troponin positive and angiographically proved CAD
but are managed medically because of financial or other rea-
sons. This subset resembles the angiographically proved CAD
subgroup of TRIOLOGY ACS. Hence the use of body weight
adjusted dose of prasugrel may be extrapolated for con-
servatively managed ACS patients who have significant cor-
onary artery disease and had suffered moderate to high risk
ACS. It will be very interesting to study themedicallymanaged
NSTEMI or UA patients andwho have angiographically proven
significant coronary artery diseasewith use of either prasugrel
or clopidogrel in addition to aspirin. For this the following
study design can be suggested.r e f e r e n c e s
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Background: Renal sympathetic nerve activation contrib-
utes to the pathogenesis of hypertension. Symplicity HTN-2, a
multicenter, randomized trial, demonstrated that catheter-
based renal denervation produced significant blood pressure
lowering in treatment-resistant patients at 6 months after the
procedure compared with control, medication-only patients.
Longer-term follow-up, including 6-month crossover results,
is now presented.
Methods and results: Eligible patients were on 3 anti-
hypertensive drugs and had a baseline systolic blood pressure
160 mm Hg (150 mm Hg for type 2 diabetics). After the
6-month primary end point was met, renal denervation in
control patients was permitted. One-year results on patients
randomized to immediate renal denervation (n ¼ 47) and
6-month postprocedure results for crossover patients are
presented. At 12 months after the procedure, the mean fall in
office systolic blood pressure in the initial renal denervation
group (28.1 mm Hg; 95% confidence interval, 35.4 to 20.7;
p < 0.001) was similar to the 6-month fall (31.7 mm Hg; 95%
confidence interval, 38.3 to 25.0; p < 0.16 versus 6-month
change). The mean systolic blood pressure of the crossover
group 6 months after the procedure was significantly lowered
(from 190.0 19.6 to 166.3 24.7mmHg; change,23.7 27.5;
p < 0.001). In the crossover group, there was 1 renal artery
dissection during guide catheter insertion, before denerva-
tion, corrected by renal artery stenting, and 1 hypotensive
episode, which resolved with medication adjustment.Conclusions: Control patients who crossed over to renal
denervationwith the Symplicity systemhad a significant drop
in blood pressure similar to that observed in patients receiving
immediate denervation. Renal denervation provides safe and
sustained reduction of blood pressure to 1 year.
Clinical trial registration: URL: http://www.clinicaltrials.
gov. Unique identifier: http://www.clinicaltrials.gov. (Circu-
lation. 2012;126:2976e2982.)1. Clinical perspective
The efficacy and safety of the Renal sympathetic Denerva-
tion (RDN) by utilizing the Symplicity Renal Denervation
System in patients with uncontrolled resistant hypertension
have been documented earlier. It has been shown that
activation of the sympathetic nervous system is involved in
the pathogenesis and maintenance of hypertension. Renal
denervation with the Symplicity catheter is a minimally
invasive procedure based on the premise that interruption
of renal afferent and efferent nerves with resultant decrease
in sympathetic outflow to the kidneys should reduce renin
release and sodium retention, increase renal blood flow, and
lower blood pressure. One-year follow-up data of The Sym-
plicity HTN-2 trial demonstrates two points: (1) that the
initial significant lowering of blood pressure achieved by the
RDN procedure was maintained at the end of one year and
no procedure-related side effect was revealed by that time;
and (2) the control patients maintained on medical therapy
and whose blood pressure was not adequately controlled
were now permitted to switch over to RDN procedure. These
patients again showed significant drop in blood pressure,
which was maintained at the end of six months. Renal
sympathetic Denervation by radiofrequency ablation thus
may provide a safe and effective adjunctive therapy for
treatment-resistant hypertensive patients.
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